Drug profile

The FDA adverse-event record for Unspecified Dexamethasone Sodium Phosphate

15 FDA reports name Unspecified Dexamethasone Sodium Phosphate, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2127 of 2,679
by report volume (all drugs)
15
adverse-event reports
20.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Dexamethasone Sodium Phosphate ranks #2072 of 2679 by total reports (15). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2072
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Dexamethasone Sodium Phosphate has 15 reports now versus 11 in that prior snapshot: 4 more (36.4%).

Report change
+4
Death-coded reports
+0
Death-coded share
−7.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Dexamethasone Sodium Phosphate changes

Signature read: 15 reports place Unspecified Dexamethasone Sodium Phosphate in the lower third of FDA AER volume (#2127 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
3
Deaths Reported
20.0%
Death-coded share of reports

Active Ingredients

Unspecified Dexamethasone Sodium Phosphate

Administration Routes

UnknownIntravenousOral

Species Affected

Dog 14
Cat 1

Most Affected Breeds

Terrier - Airedale 2
Terrier - Bull - American Pit 2
Bulldog - French 2
Domestic Shorthair 1
Siberian Husky 1
Sheepdog - Old English (Bobtail) 1
Corgi - Welsh Pembroke 1
Crossbred Canine/dog 1
Retriever - Labrador 1
Terrier (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 5
Hypokalaemia 5
Pale mucous membrane 5
Intentional misuse 5
Neutrophilia 5
Emesis (multiple) 4
Soft stool 4
Fever 4
Low platelet count 4
Not eating 4
Elevated serum alkaline phosphatase (ALP) 4
Immune mediated haemolytic anaemia 4

Outcome Breakdown

Ongoing
10 (66.7%)
Euthanized
3 (20.0%)
Recovered/Normal
2 (13.3%)

Unspecified Dexamethasone Sodium Phosphate: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Dexamethasone Sodium Phosphate (#2127 of 2,679 by report volume); death-coded 20.0%. PlainBreed drug row · report volume stamp 15 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →